血糖正常的糖尿病酮症酸中毒与并发甲状腺危象的关联性：一例报告
The Interconnectedness of Euglycemic Diabetic Ketoacidosis With Concomitant Thyroid Storm: A Case Report.
作者信息
Strawn Kevin D, Davis Keith W
机构信息
Internal Medicine, Billings Clinic, Billings, USA.
出版信息
Cureus. 2024 Apr 21;16(4):e58696. doi: 10.7759/cureus.58696. eCollection 2024 Apr.
Abstract
Sodium-glucose transport protein 2 inhibitors (SGLT2i) are becoming commonplace in many chronic diseases: type 2 diabetes mellitus, heart failure, and chronic kidney disease. We present the case of a 65-year-old male with a history of type 2 diabetes who had been on an SGLT2i for over 12 months and was found to have euglycemic diabetic ketoacidosis (eDKA) occurring concurrently with a thyroid storm. This case report illustrates a unique scenario of two endocrine emergencies occurring simultaneously.
摘要
钠-葡萄糖协同转运蛋白2抑制剂（SGLT2i）在许多慢性疾病中越来越常见：2型糖尿病、心力衰竭和慢性肾脏病。我们报告一例65岁男性，有2型糖尿病病史，服用SGLT2i超过12个月，并发甲状腺危象时出现血糖正常的糖尿病酮症酸中毒（eDKA）。本病例报告说明了两种内分泌急症同时发生的独特情况。
相似文献
1
The Interconnectedness of Euglycemic Diabetic Ketoacidosis With Concomitant Thyroid Storm: A Case Report.血糖正常的糖尿病酮症酸中毒与并发甲状腺危象的关联性：一例报告
Cureus. 2024 Apr 21;16(4):e58696. doi: 10.7759/cureus.58696. eCollection 2024 Apr.
2
Euglycemic Diabetic Ketoacidosis Induced by Sodium-Glucose Cotransporter-2 Inhibitor Use and Coronary Angiography: A Case Report.钠-葡萄糖协同转运蛋白2抑制剂使用与冠状动脉造影诱发的正常血糖性糖尿病酮症酸中毒：一例报告
Cureus. 2024 Jan 11;16(1):e52122. doi: 10.7759/cureus.52122. eCollection 2024 Jan.
3
Sodium-glucose Cotransporter-2 Inhibitors induced euglycemic diabetic ketoacidosis: A meta summary of case reports.钠-葡萄糖协同转运蛋白2抑制剂诱发的正常血糖性糖尿病酮症酸中毒：病例报告的Meta综述
World J Diabetes. 2023 Aug 15;14(8):1314-1322. doi: 10.4239/wjd.v14.i8.1314.
4
Sodium-Glucose Co-transporter 2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis After Bariatric Surgery: A Case and Literature Review.减重手术后钠-葡萄糖协同转运蛋白2抑制剂相关的正常血糖性糖尿病酮症酸中毒：一例病例及文献综述
Cureus. 2021 Aug 11;13(8):e17093. doi: 10.7759/cureus.17093. eCollection 2021 Aug.
5
A Case of SGLT2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis.1例SGLT2抑制剂所致正常血糖性糖尿病酮症酸中毒病例
Cureus. 2022 Oct 9;14(10):e30106. doi: 10.7759/cureus.30106. eCollection 2022 Oct.
6
Inpatient Perioperative Euglycemic Diabetic Ketoacidosis Due to Sodium-Glucose Cotransporter-2 Inhibitors - Lessons From a Case Series and Strategies to Decrease Incidence.钠-葡萄糖共转运蛋白 2 抑制剂致住院患者围手术期糖尿病酮症酸中毒：病例系列研究的经验教训及降低发生率的策略
Endocr Pract. 2022 Sep;28(9):884-888. doi: 10.1016/j.eprac.2022.06.006. Epub 2022 Jun 23.
7
Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitor-Related Euglycemic Diabetic Ketoacidosis: A Case Series.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂相关的正常血糖性糖尿病酮症酸中毒：病例系列
J Pharm Pract. 2025 Feb;38(1):193-197. doi: 10.1177/08971900241273169. Epub 2024 Aug 9.
8
Postcardiac Surgery Euglycemic Diabetic Ketoacidosis in Patients on Sodium-Glucose Cotransporter 2 Inhibitors.接受钠-葡萄糖协同转运蛋白2抑制剂治疗的患者心脏手术后正常血糖性糖尿病酮症酸中毒
J Cardiothorac Vasc Anesth. 2023 Jun;37(6):956-963. doi: 10.1053/j.jvca.2023.01.041. Epub 2023 Feb 7.
9
Endocrine Emergencies During Pregnancy: Diabetic Ketoacidosis and Thyroid Storm.妊娠期内分泌急症：糖尿病酮症酸中毒和甲状腺危象。
Obstet Gynecol Clin North Am. 2022 Sep;49(3):473-489. doi: 10.1016/j.ogc.2022.02.003.
10
From Sweet to Sour: SGLT-2-Inhibitor-Induced Euglycemic Diabetic Ketoacidosis.从甜蜜到酸涩：钠-葡萄糖协同转运蛋白2抑制剂诱发的正常血糖性糖尿病酮症酸中毒
J Pers Med. 2024 Jun 21;14(7):665. doi: 10.3390/jpm14070665.
引用本文的文献
1
Euglycemic Diabetic Ketoacidosis and Thyroid Storm Occurring During Dapagliflozin Treatment.达格列净治疗期间发生的正常血糖性糖尿病酮症酸中毒和甲状腺风暴
JCEM Case Rep. 2025 May 21;3(7):luaf086. doi: 10.1210/jcemcr/luaf086. eCollection 2025 Jul.
本文引用的文献
1
Heart Failure Epidemiology and Outcomes Statistics: A Report of the Heart Failure Society of America.心力衰竭流行病学与结局统计：美国心力衰竭学会报告
J Card Fail. 2023 Oct;29(10):1412-1451. doi: 10.1016/j.cardfail.2023.07.006. Epub 2023 Sep 26.
2
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2023.11. 慢性肾脏病与风险管理：2023 年糖尿病护理标准。
Diabetes Care. 2023 Jan 1;46(Suppl 1):S191-S202. doi: 10.2337/dc23-S011.
3
Empagliflozin in Patients with Chronic Kidney Disease.恩格列净在慢性肾脏病患者中的应用。
N Engl J Med. 2023 Jan 12;388(2):117-127. doi: 10.1056/NEJMoa2204233. Epub 2022 Nov 4.
4
National Trends in Use of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists by Cardiologists and Other Specialties, 2015 to 2020.2015 年至 2020 年，心脏病专家和其他专业医生使用钠-葡萄糖共转运蛋白 2 抑制剂和胰高血糖素样肽-1 受体激动剂的全国趋势。
J Am Heart Assoc. 2022 May 3;11(9):e023811. doi: 10.1161/JAHA.121.023811. Epub 2022 Apr 27.
5
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.2022年美国心脏协会/美国心脏病学会/美国心力衰竭学会心力衰竭管理指南：美国心脏病学会/美国心脏协会临床实践指南联合委员会报告
J Am Coll Cardiol. 2022 May 3;79(17):e263-e421. doi: 10.1016/j.jacc.2021.12.012. Epub 2022 Apr 1.
6
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.2022年美国心脏协会/美国心脏病学会/美国心力衰竭学会心力衰竭管理指南：美国心脏病学会/美国心脏协会临床实践指南联合委员会报告
Circulation. 2022 May 3;145(18):e895-e1032. doi: 10.1161/CIR.0000000000001063. Epub 2022 Apr 1.
7
Dapagliflozin in Patients with Chronic Kidney Disease.达格列净治疗慢性肾脏病患者。
N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816. Epub 2020 Sep 24.
8
Euglycemic diabetic ketoacidosis.血糖正常的糖尿病酮症酸中毒。
Eur J Intern Med. 2019 May;63:9-14. doi: 10.1016/j.ejim.2019.03.014. Epub 2019 Mar 23.
9
Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories.预测 250 种死因的预期寿命、损失的生命年数以及全因和特定死因死亡率：2016-2040 年 195 个国家和地区的参考和替代情景。
Lancet. 2018 Nov 10;392(10159):2052-2090. doi: 10.1016/S0140-6736(18)31694-5. Epub 2018 Oct 16.
10
Diabetes 2030: Insights from Yesterday, Today, and Future Trends.《2030年糖尿病：从过去、现在到未来趋势的洞察》
Popul Health Manag. 2017 Feb;20(1):6-12. doi: 10.1089/pop.2015.0181. Epub 2016 Apr 28.
Zotero 插件